Cover Image

Efficacy and safety of bronchoscopic lung volume reduction for chronic obstructive pulmonary disease: a systematic review and network meta-analysis

Various bronchoscopic lung volume reduction (BLVR) methods have been developed to treat chronic obstructive pulmonary disease (COPD). The efficacy and safety of these interventions remain unclear. This study assessed the efficacy and safety of various BLVR interventions in COPD patients. PubMed and...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhang, Ranran (Author) , Zheng, Ziwen (Author) , Bian, Yiding (Author) , Deng, Mingming (Author) , Herth, Felix (Author) , Hou, Gang (Author)
Format: Article (Journal)
Language:English
Published: 08 Aug 2024
In: Expert review of respiratory medicine
Year: 2024, Volume: 18, Issue: 8, Pages: 631-644
ISSN:1747-6356
DOI:10.1080/17476348.2024.2388293
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/17476348.2024.2388293
Get full text
Author Notes:Ranran Zhang, Ziwen Zheng, Yiding Bian, Mingming Deng, Felix F. J. Herth, Gang Hou
Description
Summary:Various bronchoscopic lung volume reduction (BLVR) methods have been developed to treat chronic obstructive pulmonary disease (COPD). The efficacy and safety of these interventions remain unclear. This study assessed the efficacy and safety of various BLVR interventions in COPD patients. PubMed and Embase were searched from inception to 21 October 2023. The primary outcomes assessed included the 6-min walking distance (6MWD), St. George Respiratory Questionnaire (SGRQ) score, lung function, and adverse events (AE). A frequentist approach with a random-effects model was used for a network meta-analysis. Twelve randomized controlled trials (RCTs) with 1646 patients were included in this meta-analysis. Patients treated with an endobronchial valve (EBV) achieved a minimum clinically important difference (MCID) in 6MWD and SGRQ at 6 months. Patients treated with coils achieved MCID in the SGRQ score at 12 months. Patients with aspiration valve system and bronchoscopic thermal vapor ablation (BTVA) achieved MCID in the SGRQ score at 6 months. In COPD patients, EBV should be considered first, while being wary of pneumothorax. Coil and BTVA are potential therapeutic alternatives. Although BTVA demonstrates a safer procedural profile than coils, additional studies are imperative to clarify its efficacy.
Item Description:Online veröffentlicht: 08. August 2024
Gesehen am 23.07.2025
Physical Description:Online Resource
ISSN:1747-6356
DOI:10.1080/17476348.2024.2388293

Similar Items